KAITLIN JASMON: Open Payments
NPI 1760805949 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,206 in 86 payments from 14 companies in 2025. Trend: 2023 $489 · 2024 $1,406 · 2025 $2,206
Food & beverage: $2,146Education: $60
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $375 |
| GENZYME CORPORATION | 13 | $338 |
| GlaxoSmithKline, LLC. | 12 | $269 |
| Regeneron Healthcare Solutions, Inc. | 15 | $265 |
| Boston Scientific Corporation | 1 | $257 |
| Grifols USA, LLC | 10 | $197 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $140 |
| Verona Pharma, Inc. | 6 | $99 |
| Insmed, Inc. | 4 | $72 |
| SANOFI-AVENTIS U.S. LLC | 1 | $60 |
Products named: DUPIXENT, WATCHMAN FLX, NUCALA, Prolastin-C Liquid, BREZTRI, GLASSIA, FASENRA, Ohtuvayre.
Industry payments across IN — which companies pay providers there.
